Journal
EMERGENCY MEDICINE JOURNAL
Volume 27, Issue 8, Pages 586-589Publisher
B M J PUBLISHING GROUP
DOI: 10.1136/emj.2009.079905
Keywords
-
Categories
Funding
- Heffter Research Institute, Santa Fe, New Mexico, USA
- Swiss Federal Office of Public Health, Berne, Switzerland [00.001683]
- Swiss National Foundation [323230_126231/1]
- Swiss National Science Foundation (SNF) [323230_126231] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Background MDMA (3,4-methylenedioxymethamphetamine, 'Ecstasy') produces tachycardia and hypertension and is rarely associated with cardiovascular and cerebrovascular complications. In clinical practice, beta-blockers are often withheld in patients with stimulant intoxication because they may increase hypertension and coronary artery vasospasm due to loss of beta(2)-mediated vasodilation and unopposed alpha-receptor activation. However, it is unknown whether beta-blockers affect the cardiovascular response to MDMA. Methods The effects of the non-selective beta-blocker pindolol (20 mg) on the cardiovascular effects of MDMA (1.6 mg/kg) were investigated in a double-blind placebo-controlled crossover study in 16 healthy subjects. Results Pindolol prevented MDMA-induced increases in heart rate. Peak values (mean+/-SD) for heart rate were 84+/-13 beats/min after MDMA vs 69+/-7 beats/min after pindolol-MDMA. In contrast, pindolol pretreatment had no effect on increases in mean arterial blood pressure (MAP) after MDMA. Peak MAP values were 115+/-11 mm Hg after MDMA vs 114+/-11 mm Hg after pindolol-MDMA. Pindolol did not change adverse effects of MDMA. Conclusion The results of this study indicate that beta-blockers may prevent increases in heart rate but not hypertensive and adverse effects of MDMA.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available